Core Viewpoint - Tenpoint Therapeutics, Ltd. has received FDA approval for the commercialization of BRIMOCHOL PF, an innovative eye drop treatment for presbyopia, which will be marketed as YUVEZZI in the U.S. [1] Group 1 - The approval follows the successful completion of Phase 3 clinical trials, with the first key Phase 3 study (BRIO I) demonstrating the combination therapy's superiority over individual therapies [1] - The second Phase 3 study (BRIO II) achieved all primary endpoints for near vision improvement, showing a statistically significant increase in binocular uncorrected near visual acuity (BUCNVA) by three lines or more, while binocular uncorrected distance visual acuity (BUCDVA) did not decrease by one line or more [1] Group 2 - During the BRIO II study, BRIMOCHOL PF showed good tolerability with no serious treatment-related adverse events reported, and the incidence of eye redness was low [2] - The report rate of eye redness for subjects receiving BRIMOCHOL PF was 2.8%, significantly lower than the 10.7% for those receiving only carbachol [2] Group 3 - This FDA approval serves as a strong catalyst for the company's commercialization strategy, with a partnership network established across the Asia-Pacific region and the Middle East, including eight commercial partners [2] - With FDA recognition, the company anticipates accelerating the market entry of BRIMOCHOL PF, marking an important global milestone [2]

Core Viewpoint - The approval of BRIMOCHOL™PF by the FDA represents a significant milestone for the company, enabling the commercialization of an innovative treatment for presbyopia, which is expected to accelerate the drug's market entry [1][2]. Group 1: FDA Approval and Clinical Trials - The company's partner, Tenpoint Therapeutics, received FDA approval for the commercialization of BRIMOCHOL™PF, a combination eye drop treatment for presbyopia [1]. - The approval followed successful completion of Phase 3 clinical trials, with the BRIOI study demonstrating the combination therapy's superiority over individual treatments [1]. - In the BRIOII study, BRIMOCHOL™PF met all primary endpoints for improving near vision, showing a statistically significant increase in binocular uncorrected near visual acuity (BUCNVA) by three lines or more, while maintaining binocular uncorrected distance visual acuity (BUCDVA) [1]. Group 2: Safety and Tolerability - The BRIMOCHOL™PF showed good tolerability during over 72,000 treatment days monitored in the BRIOII study, with no serious treatment-related adverse events reported [2]. - The incidence of eye redness as a side effect was low, with only 2.8% of participants in the BRIOII study reporting this compared to 10.7% in those receiving only carbachol [2]. Group 3: Commercial Strategy and Partnerships - The FDA approval serves as a strong catalyst for the company's commercialization strategy, as it has established a network of eight commercial partners across the Asia-Pacific region and the Middle East [2]. - The recognition from the FDA is expected to expedite the market entry of BRIMOCHOL™PF, marking an important global milestone for the company [2].